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Introduction. Pluripotent stem cells are believed to have greater clinical potential than mesenchymal stem cells due to their
ability to diﬀerentiate into almost any cell type of an organism, and since 2006, the generation of patient-speciﬁc induced
pluripotent stem cells (iPSCs) has become possible in multiple species. Objectives. We hypothesize that diﬀerent cell types
respond diﬀerently to the reprogramming process; thus, the goals of this study were to isolate and characterize equine adult
and fetal cells and induce these cells to pluripotency for future regenerative and translational purposes. Methods. Adult
equine ﬁbroblasts (eFibros) and mesenchymal cells derived from the bone marrow (eBMmsc), adipose tissue (eADmsc), and
umbilical cord tissue (eUCmsc) were isolated, their multipotency was characterized, and the cells were induced in vitro into
pluripotency (eiPSCs). eiPSCs were generated through a lentiviral system using the factors OCT4, SOX2, c-MYC, and KLF4.
The morphology and in vitro pluripotency maintenance potential (alkaline phosphatase detection, embryoid body formation,
in vitro spontaneous diﬀerentiation, and expression of pluripotency markers) of the eiPSCs were characterized. Additionally,
a miRNA proﬁle analysis of the mesenchymal and eiPSCs was performed. Results. Multipotent cells were successfully
isolated, but the eBMmsc failed to generate eiPSCs. The eADmsc-, eUCmsc-, and eFibros-derived iPSCs were positive for
alkaline phosphatase, OCT4 and NANOG, were exclusively dependent on bFGF, and formed embryoid bodies. The miRNA
proﬁle revealed a segregated pattern between the eiPSCs and multipotent controls: the levels of miR-302/367 and the miR-92
family were increased in the eiPSCs, while the levels of miR-23, miR-27, and miR-30, as well as the let-7 family were
increased in the nonpluripotent cells. Conclusions. We were able to generate bFGF-dependent iPSCs from eADmsc, eUCmsc,
and eFibros with human OSKM, and the miRNA proﬁle revealed that clonal lines may respond diﬀerently to the
reprogramming process.
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1. Introduction
Mesenchymal stem cells (MSCs) are spindle-shaped multi-
potent cells that are easy to isolate, readily adhere to plastic
culture dishes, and have great expansion capacity. MSCs have
been widely used for cell therapy over the last few years
despite their rare presence in tissues and their limited diﬀer-
entiation potential [1–3]. Due to their ability to diﬀerentiate
into almost any cell type of an organism, pluripotent stem
cells, such as embryonic stem cells (ESCs), are highly signiﬁ-
cant and eﬃciently isolated and maintained in vitro in
domestic species [4, 5]. Since Yamanaka’s breakthrough in
2006, it has been possible to produce patient-speciﬁc induced
pluripotent stem cells (iPSCs), which are currently available
for multiple species, including horses [6–11].
iPSCs hold great potential for use in both human and vet-
erinary regenerative medicine. The inﬂuence of the origin of
the somatic cells used in iPSC production is currently contro-
versial. Equine iPSCs have already been produced from ﬁbro-
blasts [6–10] and mesenchymal cells derived from adipose
tissue [11].
Previous reports have suggested that iPSCs may retain
residual epigenetic traces of the cell types from which they
were reprogrammed, which could aﬀect the reprogram-
ming and diﬀerentiation capacity of these cells [12]. Addi-
tionally, it has been reported that ﬁbroblasts present
inferior reprogramming rates compared with other cell
types [13]. Therefore, studies investigating multiple cell
sources from the same individuals are particularly impor-
tant for enhancing our understanding and use of these cells
for further applications.
Because of the more than 100 billion dollars invested in
horses per year [10], the severe economic losses caused by
horse musculoskeletal injuries [7], and due to the similarities
between human and horse athletes and between injuries
resulting from physical activity in both species [14], horses
can be considered excellent models for musculoskeletal
research and cell therapy.
It has been shown that miRNAs are relevant to the
regulation of reprogramming and the maintenance of plur-
ipotency and may present diﬀerent expression patterns
according to the diﬀerent pluripotency states [15]. Some
miRNA families, such as miR-302/367 and miR-92, pres-
ent increased levels in iPSCs and ESCs, while diﬀerentiated
cells present increased levels of miR-23, miR-27, and miR-
30, as well as the let-7 family [16, 17]. Thus, miRNA pro-
ﬁle analyses may provide important information regarding
pluripotency induction, speciﬁcally in those species for
which iPSC generation is not fully understood.
Herein, we aimed to obtain and characterize the follow-
ing fetal and adult equine cell lines: equine umbilical cord
tissue mesenchymal cells (eUCmsc), adipose tissue mesen-
chymal cells (eADmsc), bone marrow mesenchymal cells
(eBMmsc), and equine adult ﬁbroblasts (eFibros). These
cells were subsequently characterized and induced into
pluripotency to generate eiPSCs (eiPSCs-eADmsc, eiPSCs-
eUCmsc, eiPSCs-eBMmsc, and eiPSCs-eFibros) using
human or murine OCT4, SOX2, KLF4, and C-MYC (hOSKM
and mOSKM, respectively). The generated eiPSCs were
maintained for more than 30 passages only on bFGF supple-
mentation, and their morphology, in vitro pluripotency
maintenance potential (as measured by alkaline phosphatase
detection), in vitro spontaneous diﬀerentiation, and
pluripotency-related factor expression (asmeasured by immu-
nocytochemistry and expression of transcripts) were analyzed.
Additionally, compared to other cell types, the miRNA pro-
ﬁle of the multipotent and eiPSCs produced here suggests
that a heterogeneous reprogramming process occurred.
2. Methods
The study procedures were performed after obtaining
approval from the Ethics Committee on the Use of Animals
of the Faculty of Veterinary Medicine and Animal Sciences,
University of São Paulo (protocol 2913/2013). Unless other-
wise stated, the analyses were performed in biological tripli-
cates, and photodocumentation was performed with a
Nikon Eclipse TS100 and Nikon DS-Ri1.
2.1. Cell Line Isolation and Characterization. At least three
cell lines were isolated from diﬀerent animals per cell
type. The cells were initially cultivated in 35mm diameter
dishes using Iscove’s Modiﬁed Dulbecco’s Medium
(IMDM, Life Technologies) supplemented with 15% fetal
bovine serum (FBS, Gibco), 0.1mg/ml streptomycin, and
100U/ml penicillin (pen/strep, Gibco) at 38.5°C, 5%
CO2, and maximal humidity (standard culture conditions),
unless otherwise stated.
2.1.1. Bone Marrow Mesenchymal Stem Cells. The equine
bone marrow cells were provided by Dr. Fernanda da Cruz
Landim (São Paulo State University, UNESP, Botucatu, SP,
Brazil) and isolated as previously described [18].
2.1.2. Fibroblasts and Adipose Tissue Mesenchymal Stem
Cells. The ﬁbroblasts were obtained from skin fragments
from adult mares’ necks, and the adipose tissue mesenchymal
cell lineages were obtained from biopsies of adipose tissue
removed from the tail ply. The collected skin fragments and
adipose tissue biopsies were rinsed in a 0.9% saline solution
containing antibiotics, minced to small pieces, and digested
in 5ml of collagenase IV 0.001% (Sigma-Aldrich) for 3 h at
38.5°C. Next, the collagenase was inactivated, and the cell
precipitate was suspended in IMDM media and cultured
under standard culture conditions. The cells were passaged
before reaching 90% conﬂuency and cryopreserved for fur-
ther studies.
2.1.3. Umbilical Cord Tissue Mesenchymal Stem Cells. The
eUCmsc were derived from an umbilical cord fragment col-
lected postpartum immediately after the natural rupture of
the cord. The tissue was rinsed in a 0.9% saline solution con-
taining antibiotics, reduced into small fragments before incu-
bation, cultured in IMDM medium under standard culture
conditions, passaged before reaching 90% conﬂuency, and
cryopreserved after 48 h in culture for further studies.
2.1.4. Cell Characterization by Multilineage Diﬀerentiation.
The cells were subjected to induced diﬀerentiation using
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commercial kits (StemPro A10070-01, A10071-01, and
A10072-01; Gibco) according to the manufacturer’s instruc-
tions. Brieﬂy, for the chondrogenic cell diﬀerentiation, the
eBMmsc, eADmsc, and eUCmsc were plated in 5μl droplets
at a concentration of 1 6 × 107 cells/ml and cultured under
standard conditions for 2 h; then, the diﬀerentiation medium
was added. The medium was replaced every 4 days for 2
weeks. For the osteogenic diﬀerentiation, 5 × 103 cells/cm2
were plated and incubated for 24h; then, the IMDMmedium
was replaced by a speciﬁc diﬀerentiation medium, which
was replaced every 4 days for 2 weeks. For the adipogenic
diﬀerentiation, 1 × 104 cells/cm2 were plated and incubated
for 24 h; then, the IMDM medium was replaced by a spe-
ciﬁc diﬀerentiation medium, which was replaced every four
days for two weeks. The cells in the control group were
plated under the same conditions but were maintained in
IMDM medium. At the end of the two-week period, the
cells were ﬁxed and stained using Sudan black dye
(Sigma-Aldrich) for the adipogenesis diﬀerentiation detec-
tion, Alizarin red (Sigma-Aldrich) for the osteogenesis
detection, and Alcian blue (Sigma-Aldrich) for the chon-
drogenesis diﬀerentiation detection.
2.1.5. Analysis of Surface Markers on Mesenchymal Stem
Cells. The equine speciﬁc surface markers CD44
(MCA1082GA, AbD Serotec, Raleigh, NC, USA), CD86
(NB100-77815, BD Pharmingen), MHC I (MCA1086GA,
AbD Serotec), and MHC II (MCA1085GA, AbD Serotec)
were analyzed by ﬂow cytometry (FACSAria, BD Biosci-
ences) as previously described [19–21]. In brief, the eADmsc,
eUCmsc, eBMmsc, eFibros, and MEFs (which were used as a
negative control) were pelletized, rinsed with 0.1% BSA solu-
tion, and centrifuged at 600g for 5min (min). Subsequently,
the cells were blocked for 1 h with 10% bovine serum
albumin (BSA, Sigma-Aldrich) solution and rinsed. Then,
the cells were incubated with primary antibodies (dilution
1 : 300) for 1 h, rinsed, and pelletized again (600g, 5min).
The secondary antibody (polyclonal goat anti-mouse FITC;
dilution 1 : 300, F-0479, Dako) was added for 1 h; then, the
cells were rinsed with 2% paraformaldehyde (PFA, Synth)
solution for 10min and suspended in phosphate-buﬀered
saline (PBS, Sigma-Aldrich).
The analysis of the ﬂuorescence was performed using a
FACSAria cytometer (BD Biosciences) controlled by FACS-
Diva v.8 software (BD Biosciences). At least 1 × 105 cells
per group were analyzed to determine their size and com-
plexity (FSC × SSC) and FITC ﬂuorescence intensity (excita-
tion 488nm, emission 530nm).
2.1.6. Analysis of Cellular Doubling Time. The cell lines were
plated in 6-well plates at 3 × 104 cells/well. After 48 h in cul-
ture, the cells were counted with a Neubauer chamber and
replated at the initial ratio. This process was repeated ﬁve
times. The mean cell doubling time (DT) was calculated in
hours as previously described [22] using the equation DT =
T − T0 log 2/ log N − log N0 , where (T − T0) is the
time (hours) during which the cells were cultured between
passages, N0 is the number of cells originally plated, and
N is the number of cells harvested after 48 h of culture.
2.2. Cellular Reprogramming
2.2.1. Induction of Pluripotency. The eADmsc, eUCmsc,
eFibros, and eBMmsc were induced to pluripotency using
murine or human OCT4, SOX2, KLF4, and C-MYC
(mOSKM and hOSKM, respectively) reprogramming factors
in a lentiviral vector (STEMCCA, Millipore) [23]. Lipofec-
tion (Lipofectamine 3000, Life Technologies) was used for
the lentiviral production. In total, 6 × 106 293FT cells were
plated in 100mm diameter dishes one day before lipofection
to achieve 90% conﬂuency at the time of transfection. Twelve
micrograms of each OSKM vector, 1.2μg of each auxiliary
vectors, i.e., TAT, REV, and Hgpm2, and 2.4μg of VSVG
were used in the transfection per plate. The cells were incu-
bated with lipofection overnight, and the culture medium
was collected after 24, 48, and 72 h, ﬁltrated, and used for
the transduction.
For the transduction, 2 × 104 equine cells were previously
seeded in each well of a 6-well plate and transduced with
hOSKM or mOSKM in the presence of 8μg/ml Polybrene
(hexadimethrine bromide, Sigma-Aldrich). After six days of
culture in IMDM, the cells were harvested, plated onto feeder
layers (1 × 105 mitomycinized mouse embryonic ﬁbroblasts
(MEFs) on 6-well plates), and cultivated in KnockOut
Dulbecco’s modiﬁed Eagle’s medium (DMEM/F-12, Gibco),
10% KnockOut Serum Replacement (KSR, Gibco), 1%
antibiotics (pen/strep, Gibco), 1% L-glutamine (Gibco), 1%
nonessential amino acids (Gibco), and 0.007% β-mercap-
toethanol (Gibco) supplemented with 10ng/mL human
bFGF (PeproTech) until colonies formed. The ﬁrst passage
of each culture was performed manually for the clonal iPSC
lineage formation; then, dissociation (TrypLE Express,
Gibco) was used for replating.
2.2.2. Characterization of iPSCs: Alkaline Phosphatase
Detection, Embryoid Body (EB) Formation, Spontaneous
Diﬀerentiation In Vitro, and Immunocytochemical Analysis.
Alkaline phosphatase (AP) was detected in iPSCs using
an Alkaline Phosphatase Detection Kit (86R-1KT, Sigma-
Aldrich) according to the manufacturer’s instructions.
For the EB formation, eiPSCs were dissociated (TrypLE
Express, Gibco) for 2min, and the cell clumps were plated
in culture dishes (previously coated with 0.6% agarose to
avoid adhesion) along with iPSC culture medium without
bFGF. The EBs were cultivated for three to ﬁve days;
then, they were mechanically dissociated and plated in
IMDM and the cells were cultured for 30 days for spon-
taneous diﬀerentiation.
Immunocytochemical analysis was performed on the
cells to detect ectoderm tissue formation through neuroﬁla-
ment labeling. The cells were ﬁxed with 4% PFA for 12min
in the wells and washed with PBS 3 times for 5min per wash.
Then, the cells were permeabilized with 0.1% Triton X-100
(Labome) solution for 10min at room temperature, washed
with PBS 3 times for 5min per wash, and blocked with 1%
BSA/0.1% Tween 20 (Biocare Medical) solution for 30min
at room temperature. Then, the cells were labeled with the
primary antibody (Neuroﬁlament, N4142, Sigma-Aldrich;
1 : 100 dilution) overnight, washed with PBS 3 times, and
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labeled with secondary antibodies (anti-rabbit 488, A11034,
Invitrogen; 1 : 300 dilution) for 1 h.
2.2.3. OCT4 Immunocytochemical Analyses in 24-Well Plates.
The eiPSCs were cultured in the proper medium until colo-
nies were apparent; then, the cells were ﬁxed, permeabilized,
blocked, and labeled with a primary OCT4 antibody (anti-
goat Sc8628, Santa Cruz Biotechnology; 1 : 100 dilution)
and secondary antibody (anti-goat Alexa Fluor 488,
A11078; 1 : 300 dilution, Invitrogen) as described above.
The cells were washed 3 times with PBS for 5min per wash,
labeled with Hoechst 33342 (1 : 1000 dilution, Sigma-
Aldrich) for 5min, and washed again with PBS. In both anal-
yses, noninduced cells were used as negative controls.
2.2.4. Detection of Transcripts Related to Pluripotency and
Reprogramming Vectors. For the total RNA extraction, the
cells were pelleted at passages 5-7 by centrifugation, frozen
in liquid nitrogen, and stored in a freezer at -80°C. The
RNA was isolated with the TRIzol Reagent (Invitrogen),
and the extraction was carried out using a miRNeasy Mini
Kit (Qiagen) according to the manufacturer’s instructions.
After the DNase treatment, a NanoDrop 2000 (Thermo
Fisher Scientiﬁc) was used to measure the total RNA, and
the RNA quality was evaluated by the 260/280 ratio. The
cDNA synthesis was performed with a high-capacity cDNA
reverse transcription kit (Applied Biosystems) according to
the manufacturer’s instructions.
A conventional PCR analysis was performed to detect the
expression of genes related to pluripotency (NANOG and
OCT4) and the exogenous reprogramming vector (Table 1).
NANOG was analyzed since it is not included in the repro-
gramming vector; therefore, its presence, which is exclusively
endogenous, may be considered an indicator of reprogram-
ming. OCT4 was also analyzed because of its importance
for the reprogramming process and because of its expression
from both endogenous and exogenous cDNAs.
To analyze the transcripts related to pluripotency, we
performed a 25μl PCR reaction containing 12.5μl of 2xMas-
ter Mix (BioLab), 200 nM of speciﬁc reverse primer and for-
ward primer, 1μl of cDNA, and diethyl pyrocarbonate
(DEPC) water in a ﬁnal volume of 25μl. The PCR reaction
was performed under the following cycle conditions: 95°C
for 1min; 35 cycles of 95°C for 30 seconds (s), 57.5°C for
1min, and 68°C for 1min; and ﬁnally, 68°C for another
5min; the amplicon was conﬁrmed by agarose gel (1.5%)
electrophoresis. Additionally, to detect the presence of the
reprogramming vector, DNA was isolated using a commer-
cial DNeasy Blood and Tissue Kit (Qiagen). The PCR reac-
tion was performed using the same concentrations and
volumes used for the OCT4 and NANOG PCR reactions;
however, the annealing temperature was 60°C. GAPDH was
used as a housekeeping gene for the vector integration and
expression, and eADmsc, eUCmsc, and eFibros were used
as negative controls for the NANOG and OCT4 detection.
The amplicon was conﬁrmed by agarose gel electrophoresis.
2.3. miRNA Proﬁle Analysis. The miRNA expression proﬁles
of eFibros, eADmsc, eUCmsc, and their derived iPSCs, as
well as the MEFs used for the iPSC culture were analyzed.
The RNA extraction was performed with a miRNeasy Mini
Kit (Qiagen). A miScript PCR System (Qiagen) was used
for the miRNA reverse transcription according to the manu-
facturer’s instructions. Then, 100ng of total RNA was con-
verted by RT-PCR to cDNA and used for the expression
analyses of 126 miRNAs (124 target miRNAs and 2 house-
keeping genes, Supplementary material 1). Brieﬂy, the RNA
was incubated with 5x miScript HiFlex Buﬀer, 10x miScript
Nucleic Mix, RNase-free water, and miScript Reverse Tran-
scriptase at 37°C for 60min, followed by 5min at 95°C. An
RT-qPCR reaction was set up in a volume of 10μl containing
2x QuantiTect SYBR Green (Qiagen), 10μM each of a uni-
versal reverse primer (Qiagen) and miRNA-speciﬁc forward
primer, and 0.03μl of 1 : 4 diluted cDNA, and the qPCR reac-
tion was carried out using a QuantStudio 6 Flex PCR System
(Applied Biosystems) under the following cycle conditions:
95°C for 15min; 45 cycles of 94°C for 10 s, 55°C for 30 s,
and 72°C for 30 s. The amplicon was conﬁrmed by a melting
curve analysis. The Ct values were normalized to the geomet-
ric mean of RNT43 snoRNA, Hm/Ms/Rt T1 snRNA, and
bta-mir-99b. After normalizing the data using the geometric
mean of three miRNAs detected in the groups, the cycle
thresholds and transcript levels were calculated using the 2-
ΔCt method [24]. After evaluating homology among human
and equine miRNAs, the software mirPath v.3 (DIANA
TOOLS) was used to identify the pathways related to the
miRNAs found in each group.
2.4. Statistical Analysis. Statistical analyses of cellular dou-
bling time, surface markers, and colony production eﬃciency
were carried out using an analysis of variance, followed by a
Tukey test at a signiﬁcance level of 5%. The results are
expressed as the means ± standard deviation.
For miRNA proﬁle analyses, comparisons between con-
trol and treated cells for each group (eUCmsc, eFibros, and
eADmsc) were made by a two-tailed Student t-test following
two-sample and homoscedastic parameters, at a signiﬁcance
level of 5%. The results are expressed as the means ±
standard deviation. The heat map and principal component
analysis were performed after the normalized CT values (2-
ΔCt) of all 110 miRNA commonly detected in all three cell
types that were exported and processed using Metaboanalyst
3.0 (http://www.metaboanalyst.ca) [25].
3. Results
3.1. Cell Line Isolation and Characterization
3.1.1. Multilineage Diﬀerentiation. Three eADmsc, 3 eFibros,
3 eUCmsc (Figures 1(a), 1(b), and 1(c), respectively), and 3
eBMmsc (Supplementary material 2) cell lines were success-
fully isolated, and their induced diﬀerentiation as indicated
by morphological diﬀerences between the diﬀerentiated cells
and negative control cells was analyzed. Adipogenic diﬀeren-
tiated cells were characterized by lipid vacuole accumulation
(Figures 1(a i), 1(b i), and 1(c i)), osteogenic diﬀerentiated cells
were characterized by calcium deposition (Figures 1(a ii), 1(b
ii), and 1(c ii)), and chondrogenic diﬀerentiated cells were
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characterized by chondrogenic pellet development
(Figures 1(a iii), 1(b iii), and1(c iii)), while the negative con-
trol cells maintained the typical spindle-like shape.
3.1.2. Analysis of Surface Markers on Mesenchymal Cells. The
cell lineages presented high percentages of expression of
CD44 (eADmsc, 92 5 ± 11 9; eUCmsc, 93 4 ± 5 1; eBMmsc,
86 ± 15 1; and eFibros, 89 7 ± 7 5) and MHC I (eADmsc, 84
± 7 5; eUCmsc, 81 2 ± 17 8; eBMmsc, 61 ± 4 5; and eFibros,
94 13 ± 7 52) and low percentages of expression of CD86
(eADmsc, 1 8 ± 1 3; eUCmsc, 1 2 ± 0 7; eBMmsc, 6 4 ± 5 1;
and eFibros, 0 6 ± 0 1) and MHC II (eADmsc, 3 ± 0 5;
eUCmsc, 5 4 ± 1 9; eBMmsc, 13 2 ± 10; and eFibros, 5 7 ±
1 6—Table 2). No signiﬁcantly diﬀerent results were detected,
which is consistent with the already described data of the
equine surface markers.
3.1.3. Analysis of Cellular Doubling Time. The doubling time
assay was determined in hours, and the following results
were obtained: 58 ± 14 h for eBMmsc, 46 ± 12 h for
eUCmsc, 29 ± 9 h for eFIBROs, and 23 ± 11 h for eADmsc
(Supplementary material 3). eADmsc and eFibros presented
a signiﬁcantly lower doubling time compared to eUCmsc
and eBMmsc (P < 0 05).
3.2. Cellular Reprogramming
3.2.1. Induction of Pluripotency. The equine cells were
induced into pluripotency using human or murine OKSM.
Using hOSKM (Figure 2), eUCmsc were the ﬁrst lineage
to present iPSC colony formation (11 days after pluripo-
tency induction), followed by eADmsc (13 days after plur-
ipotency induction), and ﬁnally, eFibros (15 days after
pluripotency induction). Using mOSKM, only eADmsc
presented colony formation in one repetition; however,
this result was not reproducible (P < 0 05) (Figure 2(e)).
It was not possible to produce eiPSCs from eBMmsc in the
present study using either of the reprogramming systems
(Supplementary material 2).
In the comparison of the eiPSC production eﬃciency
among the diﬀerent lineages produced here, using 24 × 104
cells induced to pluripotency, eiPSCs-eADmsc (n = 322,
P < 0 01) presented the highest colony formation, followed
by eiPSCs-eFibros (n = 65) and eiPSCs-eUCmsc (n = 58);
the ﬁnal two lineages did not diﬀer (P = 0 95, Table 3).
In total, 85 iPS clonal cell lines were generated, further
maintained in vitro at initial passages, and cryopreserved
(human reprogramming factors: n = 30 for eiPSCs-eFibros,
n = 33 for eiPSCs-eADmsc, and n = 21 for eiPSCs-eUCmsc;
mouse reprogramming factors: n = 1 for eiPSCs-eADmsc)
(Table 3), suggesting that human reprogramming factors
are more eﬀective in reprogramming equine cells in this
study. At least one clonal eiPCS line from each group was
maintained in vitro for at least 30 passages. Additionally,
the equine iPSCs produced here are dependent only on
bFGF, dismissing the need for LIF supplementation.
3.2.2. eiPSC Characterization. eiPSCs-eADmsc, eiPSCs-eFi-
bros, and eiPSCs-eUCmsc were positive for AP (Figures 2(a i),
2(b i), and 2(c i), respectively) and OCT4 (Figures 2(a ii), 2(b
ii), and 2(c ii), respectively) as detected through immunocyto-
chemistry. We were also able to detect higher levels of expres-
sion of bothNANOG (Figure 2(d i)) andOCT4 (Figure 2(d ii))
after pluripotency induction in all cell lines analyzed. The
vector expression was conﬁrmed in eiPSCs between passages
5 and 7, indicating that the exogenous vectors were not
silenced until then (Figure 2(d iv)). The eiPSCs were also
positive for EB formation (Figures 3(a), 3(b), and 3(c)) and
in vitro spontaneous diﬀerentiation, which was characterized
by more elongated morphology and positive neuroﬁlament
labeling (Figures 3(a ii), 3(b ii), and 3(c ii)).
3.3. Global miRNA Proﬁle Analysis. The relative levels of 124
equine target miRNAs were analyzed in eADmsc, eUCmsc,
and eFibros before and after pluripotency induction. Of
these, 123 miRNAs were detected in the eUCmsc group,
124 miRNAs were detected in the eFibros group, and 123
miRNAs were detected in the eADmsc group. Analysis per-
formed with the 110 miRNAs commonly detected for the
three groups of cells demonstrated some downregulation of
miRNAs in the investigated eiPSCs compared with the levels
in the controls (Figures 4(a) and 4(b); Supplemental
Figure 11).
By performing a principal component analysis (PCA),
despite the relatively high variation in the reprogramming
process, we can observe a slight diﬀerence and clustering
between the eiPSCs and cells prior to reprogramming
(Figure 4(a)). Thus, based on miRNA expression and the
multivariate analysis approach using PCA analysis, it seems
Table 1: Speciﬁc equine primers used for the detection of endogenous and exogenous transcripts related to pluripotency and the
reprogramming vector.
Target Sequence 5′-3′ Fragment length (bp) Reference
eOCT4
F: TAGGGTTAGAGCTGCCCCCTC
199 XM_014734675.1
R: GTTTGTGTTGTCCCTCCCCCA
eNANOG
F: ACTGCTCATTCAGGACAGCC
200 XM_014740545.1
R: TCTGCTGGAGGCTGAGGTAT
eGAPDH
F: GTTTGTGATGGGCGTGAACC
205 NM_001163856.1
R: ATCGCGCCACATCTTCCC
hSTEMCCA
F: AAGAGGACTTGTTGCGGAAA
182 Sommer et al., 2009 [23]
R: GGCATTAAAGCAGCGTATCC
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that the cells prior to and after induction present some clus-
tering, although some eiPSCs do not present a similar pattern
within cell lines, suggesting heterogeneous cell populations in
each group.
3.3.1. Diﬀerential miRNA Proﬁle between Fibroblasts and
eiPSCs-eFibros. Of the 124 equine miRNAs in the equine
ﬁbroblasts prior to and after pluripotency induction, 114
miRNAs were detected in both the control cells and eiPSCs.
Of these 114 miRNAs, 10 miRNAs were diﬀerentially
expressed between the control cells and iPSCs. The miRNAs
eca-miR-92b, eca-miR-486-5p, eca-miR-494, eca-miR-302b,
and eca-miR-302d were upregulated in the iPSCs compared
with their levels in the control cells (Figure 4(d)). Further
analysis of the ﬁve upregulated miRNAs in the eiPSCs pre-
dicted the regulation of 24 signaling pathways (Supplemen-
tary material 4), including the regulation of the stem cell
pluripotency pathway.
Similarly, eca-let-7d, eca-let-7f, eca-miR-23a, eca-miR-
23b, and eca-miR-27a were downregulated in the iPSCs
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Figure 1: (a) Adipose tissue mesenchymal cells, (b) ﬁbroblasts, and (c) umbilical cord tissue mesenchymal cells, 200x. After multilineage
diﬀerentiation, it is possible to observe (a i, b i, and c i) adipogenic diﬀerentiated cells characterized by Sudan black-stained lipid vacuole
accumulation, 200x; (a ii, b ii, and c ii) osteogenic diﬀerentiated cells characterized by calcium deposition, which were stained with alizarin
red, 100x; and (a iii, b iii, and c iii) chondrogenic diﬀerentiated cells characterized by chondrogenic pellet development, which were
stained with Alcian blue, 200x. Negative control cells maintained the typical spindle-like shape and diﬀered from the treated cells.
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compared with their levels in the control cells (Figure 4(d)).
Interestingly, the analysis of the ﬁve downregulated miRNAs
predicted the regulation of 56 signaling pathways (Supple-
mentary material 5). Among the regulated pathways, stem
cell pluripotency was predicted to be regulated by miRNAs
diﬀerently expressed between the iPSCs and control cell lines
from ﬁbroblasts. Interestingly, 41 genes were predicted to be
regulated by the upregulated miRNAs in the iPSCs, while 67
genes were predicted to be regulated by the miRNAs upregu-
lated in the control cells. Remarkably, POU5F andMYC were
predicted to be regulated by the miRNAs present in the con-
trol cells and not in the eiPSCs. Thus, these results demon-
strate that the induction of pluripotency is capable of
changing the miRNA levels in eiPSCs derived from eFibros.
We also evaluated the number of miRNAs identiﬁed
exclusively in each cell group (Figure 4(di)). Of these miR-
NAs, 608 genes involved in 18 pathways were identiﬁed to
be regulated by miRNAs exclusively detected in eiPSCs-eFi-
bros, including the regulation of stem cell pluripotency,
which is predicted to be regulated by ﬁve miRNAs regulating
58 genes. eca-miR-133a, which was detected exclusively in
eFibros, regulates 23 genes involved in ﬁve pathways (Sup-
plementary material 6).
3.3.2. Diﬀerential miRNA Proﬁle between eUCmsc and
eiPSCs-eUCmsc. Of the 124 miRNAs analyzed in the equine
umbilical cord cells prior to and after pluripotency induction,
118 miRNAs were detected in multiple cell lines, and ﬁve
miRNAs were detected exclusively in eiPSCs-eUCmsc. Of
these 118 miRNAs, three miRNAs were diﬀerently detected
between control cells and eiPSCs. miRNA-302d was upregu-
lated in the eiPSCs compared with its level in the controls,
while miR-23a and miR-99a were downregulated in
eiPSCs-eUCmsc compared with their levels in the eUCmsc
(Figure 4(e)).
Further analysis of miR-302d predicted the regulation of
11 signaling pathways (Supplementary material 7), whereas
the bioinformatics analysis of miR-23a and miR-99a pre-
dicted the regulation of 20 signaling pathways (Supplemen-
tary material 8). Among the regulated pathways, the
regulation of Wnt signaling and fatty acid biosynthesis was
predicted to be regulated by miRNAs diﬀerently expressed
between the iPCSs and control cell lines from the umbilical
cord. The analysis of the ﬁve miRNAs exclusively detected
in eiPSCs-eUCmsc (Figure 4(ei)) predicted the regulation of
35 signaling pathways; among the regulated pathways, the
regulation of stem cell pluripotency (Supplementary material
6) is predicted to regulate 38 genes.
3.3.3. Diﬀerential miRNA Proﬁle between eADmsc and
eiPSCs-eADmsc. Our analysis revealed that 121 miRNAs
were shared between eiPSCs-eADmsc and eADmsc, and
two miRNAs (eca-miR-1; eca-miR-450a) were detected
exclusively in eADmsc (Figure 4(ci)). Those miRNAs are
predicted to regulate over 70 gene-related pathways with-
out direct correlation to the mechanisms of pluripotency
acquisition or maintenance. Of the 121 miRNAs, 48 miR-
NAs were diﬀerentially expressed between the iPSCs and
control cell lines (Figure 4(c)), and these miRNAs were
all upregulated in the eADmsc compared with their levels
in eiPSCs-eADmsc.
The analysis of the 48 miRNAs predicted the regulation
of 68 signaling pathways (Supplementary material 9).
Among the predicted pathways, the bioinformatics analysis
identiﬁed 119 targets within the pathways regulating pluripo-
tency and stem cells (Supplementary material 6). As
expected, the miRNAs upregulated in the control cells regu-
late genes such as SOX2, NANOG, and POU5F and iPSC
response genes such as PCGF2, FGF2, TGF3, SKIL, REST,
KAT6A, LEFTY2, PAX6, HOXB1, HAND1, NEUROG1,
and ISL1. The downregulation of these 48 miRNAs in the
eiPSCs indicates that there is decreased control over the
expression of pluripotency factors, suggesting eﬃcient repro-
gramming. Nevertheless, in contrast to the other cell types
studied here, the eca-miR-302 family did not express diﬀer-
ently in the eADmsc-derived eiPSCs. This miRNA is detected
in these cells (Supplementary materials 10 and 11); however,
no signiﬁcant diﬀerences were detected probably due to the
variation among the cell lines analyzed (Figure 4(c)).
4. Discussion
4.1. Isolation and Characterization of Equine Mesenchymal
Stem Cells. MSCs are known to present speciﬁc characteris-
tics, such as adherence to plastic; the capacity for in vitro tri-
lineage diﬀerentiation under preestablished conditions; the
expression of CD44, CD73, CD90, CD105, and MHC I; and
the absence of CD34, CD45, CD14 or CD11b, CD79,
CD86, CD19, and MHC II expression [19–21, 26]. In this
study, equine MSCs and ﬁbroblasts were isolated and they
presented plastic adherence competence. Their potential for
diﬀerentiating into osteogenic, adipogenic, and chondro-
genic cells was successfully characterized according to previ-
ously described protocols using equine cells [27]. Their
immunophenotypic proﬁles showed high expression of
CD44 and MHC I and low expression of CD86 and MHC
II. eUCmsc and eBMmsc presented signiﬁcantly longer dou-
bling time rates than eADmsc and eFibros (P < 0 05). Cell
proliferation rates are known to vary according to cell origin
[28, 29] and donor age [30, 31] and even among horse breeds
and individuals [32], which might explain the diﬀerences
found among the diﬀerent cell types studied here.
4.2. Cellular Reprogramming. Equine iPSCs have already
been produced through a PiggyBac-transposon system
Table 2: Percentage of the mean ﬂuorescence of the surface markers
CD44, CD86, MHCI, andMHCII in all equine somatic cells studied.
After the ﬂow cytometric analysis, the elevated expression of CD44
and MHCI and decreased expression of CD86 and MHCII were
detected. No signiﬁcantly diﬀerent results were detected.
eADmsc (%) eUCmsc (%) eBMmsc (%) eFibros (%)
CD44 92 5 ± 11 9 93 4 ± 5 1 86 ± 15 1 89 7 ± 7 5
CD86 1 8 ± 1 3 1 2 ± 0 7 6 4 ± 5 1 0 6 ± 0 1
MHC I 84 ± 7 5 81 2 ± 17 8 61 ± 4 5 94 13 ± 7 52
MHC II 3 ± 0 5 5 4 ± 1 9 13 2 ± 10 5 7 ± 1 6
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Figure 2: Equine iPSCs on day 18 after transduction from (a) adipose tissue mesenchymal cells, (b) ﬁbroblasts, and (c) umbilical cord tissue
mesenchymal cells, 200x. Alkaline phosphatase-positive equine iPSC colonies were induced from each cell type: (a) adipose tissue
mesenchymal cells, 100x; (b) ﬁbroblasts, 200x; (c) umbilical cord tissue mesenchymal cells, 100x. In addition, images present the
immunocytochemistry expression of merged OCT4, OCT4/FITC, and Hoechst staining: (a) adipose tissue mesenchymal cells, 100x; (b)
ﬁbroblasts, 200x; (c) umbilical cord tissue mesenchymal cells, 100x. (d) Transcript expression of GAPDH, NANOG, and OCT4 in equine
adipose tissue mesenchymal cells, umbilical cord tissue mesenchymal cells, and ﬁbroblasts before and after pluripotency induction.
NANOG and OCT4 expression levels are enhanced after cell reprogramming. Also in (d), conﬁrmation of GAPDH and STEMCCA
expression in equine iPSCs by conventional PCR. (e) Graph showing the total production of eiPSC colonies using hOSKM. No colonies
were formed from the bone marrow mesenchymal cells. Diﬀerent letters indicate signiﬁcantly diﬀerent results (P < 0 05).
8 Stem Cells International
carrying mouse OCT4, SOX2, KLF4, and c-MYC factors
(mOSKM) from fetal ﬁbroblasts [6]; adult ﬁbroblasts were
induced to pluripotency through Moloney murine leukemia
virus vectors using the human OCT4, KLF4, and SOX2
genes [7] with the addition of C-MYC to produce LIF- (leu-
kemia inhibitory factor-) dependent eiPSCs [9] using
mOSKM in foal and adult ﬁbroblasts [8]. Additionally,
eiPSCs from ﬁlly keratinocytes have been reported [10].
Recently, eiPSCs were produced from eADmsc from a
young horse using a TetO inducible lentiviral vector con-
taining mOSKM [11].
Here, we produced eiPSCs derived from adipose tissue
mesenchymal cells, umbilical cord tissue mesenchymal cells,
and adult equine ﬁbroblasts using a polycistronic excisable
lentivirus system [23] containing hOSKM (Table 3). Similar
to the equine iPSCs produced by other groups [6–11], the
eiPSCs produced here were positive for OCT4 and NANOG.
Since NANOG expression in this reprogramming system is
endogenous, the expression of this transcription factor after
pluripotency induction is indicative of the intrinsic reactiva-
tion of endogenous pluripotent-related genes.
eiPSCs-eADmsc, eiPSCs-eUCmsc, and eiPSCs-eFibros
produced here are positive for AP, EB formation, in vitro
spontaneous diﬀerentiation, and neuroﬁlament labeling after
the diﬀerentiation of EBs, all of which are signiﬁcant charac-
teristics of pluripotent cells.
Meanwhile, in contrast to other established eiPSCs
[6–11], the cells produced here are exclusively dependent
on bFGF, dismissing the need for supplementation with
LIF. This characteristic may be related to the reprogram-
ming system, which diﬀers from those previously used.
On the 11th day after reprogramming, eiPSCs-eUCmsc
began to present colonies, followed by eADmsc on the 13th
day and eFibros on the 15th day. After 20 days in culture,
eiPSCs-eADmsc presented the highest number of colonies,
followed by eiPSCs-eUCmsc and eiPSCs-eFibros (P < 0 05).
This diﬀerentiated behavior among the cell lines was
expected as it has been shown that even after reprogram-
ming, cells may retain a residual epigenetic memory that
may aﬀect their capability for reprogramming and diﬀerenti-
ation [12], leading us to believe that the cells studied here
were subjected to this eﬀect. Considering that eADmsc and
eUCmsc are less diﬀerentiated than ﬁbroblasts [14], we
expected that these cells would present a higher reprogram-
ming rate. Moreover, it has been reported that human ﬁbro-
blasts present lower reprogramming rates than other lineages
[13] as conﬁrmed by Sharma et al. [10], who reported a
higher iPSC production eﬃciency using keratinocytes com-
pared to ﬁbroblasts.
It was not possible to derive eiPSCs from bone marrow
mesenchymal cells, and it has been demonstrated that cell
reprogramming and pluripotency maintenance are closely
related to high cellular proliferation rates [33]; since eBMmsc
presented the longest doubling time among the studied cells
in this experiment, it was expected that these cells would
present a low reprogramming eﬃciency.
4.3. miRNA Proﬁle Analyses. The miRNA proﬁle analyses of
the cells in this study showed moderate segregation of
eiPSCs-eADmsc, one cell line of eiPSCs-eUCmsc, and
eiPSCs-eFibros from the other eiPSCs and control cells
(Figure 4(a); Supplemental Figure 11). These results are
consistent with the observations made during cell culture
and characterization in which eiPSCs-eADmsc responded
better to the reprogramming process and eiPSCs-eUCmsc
and eiPSCs-eFibros that were grouped with eiPSCs-eADmsc
presented the greatest EB formation eﬃciency in their
respective groups, which is indicative of reprogramming.
This ﬁnding may suggest that the eiPSCs that clustered with
the control cells present colonies with more heterogeneous
cell populations than the other lineages or might be
unevenly reprogrammed. This also aﬀected the segregation
between diﬀerent studied groups in the PCA, making the
clustering pattern less pronounced.
Likewise, we observed the presence of miRNAs regulat-
ing pluripotency-related genes on cells after pluripotency
induction (Figures 4(d) and 4(e)). The members of the
miR-302-367 family are known to regulate the levels of plur-
ipotency markers [34], and these miRNAs seem to play a
more important role during cellular reprograming than other
miRNAs and eca-miR-92. These miRNAs are also increased
in ESCs and human iPSCs [16, 17]. Interestingly, the miR-
NAs from the miR-302/367 family are enhanced in eiPSCs-
eFibros and eiPSCs-eUCmsc but not in eiPSCs-eADmsc,
probably due to the variation presented in these cells (Sup-
plementary material 10). Furthermore, miR-21, miR-122,
miR-128, and the miR-34 family were all predicted to regu-
late the expression of the OCT4, NANOG, and SOX2 genes,
which are increased in eADmsc, in contrast to the ﬁndings of
eiPSCs-eADmsc. Increased levels of miR-302/367 and the
miR-92 family were found in iPSCs and ESCs, while the miR-
NAs miR-23, miR-27, and miR-30, as well as the let-7 family
were increased in the control ﬁbroblasts [16, 17]. Similar
expression patterns were found in the eiPSCs studied here
and their respective controls. The increased expression of
the miRNAs miR-21, miR-23, and miR-206 was found in
ﬁbroblasts compared to their levels in porcine iPSCs [15],
as we found in our control cells. Moreover, these authors
observed that porcine iPSCs with higher expression of
the miR-302 family also had a higher reprogramming
eﬃciency [15].
Table 3: Total number of eiPSC colonies produced and cells lines
isolated from eBMmsc, eUCmsc, eADmsc and eFibros using
human (hOSKM) and murine (mOSKM) reprogramming factors.
Cell type
Reprogramming
factor
Number of colonies
observed at p0
Isolated
cell lines
eBMmsc
hOSKM 0 0
mOSKM 0 0
eUCmsc
hOSKM 58 21
mOSKM 0 0
eADmsc
hOSKM 322 33
mOSKM 1 1
eFibros
hOSKM 65 30
mOSKM 0 0
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The results found here are consistent with those reported
by Porciuncula et al. in 2013 [35], who characterized the
reprogramming process to which pluripotency-induced cells
were submitted.
Additionally, increases in the miRNAs miR-23 and
miR-27 and the let-7 family can be observed in the negative
control cells in this study as observed byWilson et al. in 2009
[16] in their diﬀerentiated cells, and a decrease in these miR-
NAs in eiPSCs is an indication of reprogramming. The
overall results of the eiPSC miRNA proﬁle analyses suggest
that eiPSCs-eADmsc were more evenly reprogrammed than
eiPSCs-eFibros and eiPSCs-eUCmsc.
5. Conclusion
In this study, it was possible to isolate and characterize fetal-
and adult-derived equine cell lines that were submitted to
induced reprogramming in vitro. We have shown that it is
possible to generate eiPSCs-eADmsc, eiPSCs-eUCmsc, and
eiPSCs-eFibros using human reprogramming factors. Under
our conditions, it was not possible to generate eiPSCs derived
from bone marrow mesenchymal cells, and the use of
hOSKM was more eﬃcient than the use of murine factors
in the production of equine iPSCs. This conclusion was
based on the greater number of colonies found in the cells
reprogrammed by hOSKM and the absence of reproduc-
ibility in the generation of eiPSCs from mOSKM. Further-
more, the eiPSCs produced in this study are exclusively
dependent on bFGF.
The generation of eiPSCs-eADmsc was more eﬃcient
than the generation of eiPSCs-eFibros and eiPSCs-
eUCmsc. This result corroborated the analysis of the
miRNA proﬁles of the studied cell lines before and after
reprogramming, which showed that two eiPSCs-eUCmsc
and eiPSCs-eFibros lines’ proﬁles were more similar to
their controls than the other generated eiPSCs, which is a
possible indication of heterogeneous populations among
colonies or even of partially reprogrammed cells. These
results are consistent with the hypothesis that the cell types
studied in this work might respond diﬀerently to the pro-
cess of reprogramming as shown in the eﬃciency of induc-
tion to pluripotency and the characteristics exhibited by
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Figure 4: Continued.
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the generated eiPSCs. Notably, further studies aiming at
characterizing these cells’ pluripotentiality and functional-
ity in vitro and in vivo are still necessary. Hence, a better
understanding of the stable and reproducible reprogram-
ming process constitutes an important step towards clini-
cal trials.
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Supplementary 3. Figure S2: doubling time assay. The graph
shows the doubling time (hours) assay of adipose tissue mes-
enchymal cells (eADmsc), ﬁbroblasts (eFibros), umbilical
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and eBMmsc. Diﬀerent letters indicate signiﬁcantly diﬀerent
results (P < 0 05). Graph showing results of the doubling
time assay of equine mesenchymal cells and ﬁbroblasts.
Supplementary 4. Chart S1: pathways regulated by miRNAs
increased in eiPSCs-eFibros. List of the pathways regulated
by miRNAs increased in eiPSCs derived from ﬁbroblasts.
Supplementary 5. Chart S2: pathways regulated by miRNAs
increased in ﬁbroblasts. List of the pathways regulated
by miRNAs increased in ﬁbroblasts prior to pluripotency
induction.
Supplementary 6. Figure S3: signaling pathways regulating
pluripotency of stem cells. Signaling pathways regulating
pluripotency of stem cells, regulated by miRNAs found on
eiPSCs derived from eADmsc, UCmsc, and eFibros (KEGG
PATHWAY Database). Signaling pathways regulating pluri-
potency of stem cells.
Supplementary 7. Chart S3: pathways regulated by miRNAs
increased in eiPSCs-eUCmsc. List of the pathways regulated
by miRNAs increased in eiPSCs derived from umbilical cord
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Supplementary 8. Chart S4: pathways regulated by miRNAs
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mesenchymal cells prior to pluripotency induction.
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mesenchymal cells prior to pluripotency induction.
Supplementary 10. Figure S4: Eca-miR-302 family expression
levels on eiPSCs and control cells. The miR-302 family is
associated with the maintenance of pluripotency. Although
it is not statistically signiﬁcant in eiPSCs derived from
adipose tissue mesenchymal cells, the expression of these
miRNAs is detectable in the all eiPSCs studied here. Normal-
ized concentration of the eca-miR-302 family on eiPSCs and
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Supplementary 11. Figure S5: heatmap of the 110 miRNAs
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